Regulation of CLU gene expression by oncogenes and epigenetic factors: Implications for tumorigenesis

Advances in Cancer Research

Volumn 105, Issue , 2009, Pages 115-132

  Sala, Arturo ^a   Bettuzzi, Saverio ^b,c   Pucci, Sabina ^d   Chayka, Olesya ^a   Dews, Michael ^e   Thomas Tikhonenko, Andrei ^e  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF PARMA   (Italy)

^c NATIONAL INSTITUTE OF BIOSTRUCTURES AND BIOSYSTEMS   (Italy)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLUSTERIN; EARLY GROWTH RESPONSE FACTOR 1; EGR1 PROTEIN, HUMAN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TCF7 PROTEIN, HUMAN; TRANSCRIPTION FACTOR 7;

ANIMAL; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; HUMAN; NEOPLASM; ONCOGENE; ONCOGENE MYB; ONCOGENE MYC; PHYSIOLOGY; REVIEW;

ANIMALS; CLUSTERIN; EARLY GROWTH RESPONSE PROTEIN 1; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION; GENES, MYB; GENES, MYC; HUMANS; NEOPLASMS; NF-KAPPA B; ONCOGENES; T CELL TRANSCRIPTION FACTOR 1;

EID: 73949152541     PISSN: 0065230X     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-230X(09)05007-6     Document Type: Article

References (84)

1. Arango, D., Corner, G. A., Wadler, S., Catalano, P. J., and Augenlicht, L. H. (2001). c-myc/p53 interaction determines sensitivity of human colon carcinoma cells to 5-fluorouracil in vitro and in vivo. Cancer Res. 61, 4910-4915.
2. Bettuzzi, S., Davalli, P., Astancolle, S., Carani, C., Madeo, B., Tampieri, A., Corti, A., Saverio, B., Pierpaola, D., Serenella, A., Cesare, C., Bruno, M., et al. (2000). Tumor progression is accompanied by significant changes in the levels of expression of polyamine metabolism regulatory genes and clusterin (sulfated glycoprotein 2) in human prostate cancer specimens. Cancer Res. 60, 28-34.
3. Bettuzzi, S., Scorcioni, F., Astancolle, S., Davalli, P., Scaltriti, M., and Corti, A. (2002). Clusterin (SGP-2) transient overexpression decreases proliferation rate of SV40-immortalized human prostate epithelial cells by slowing down cell cycle progression. Oncogene 21, 4328-4334.
4. Bey, E. A., Wuerzberger-Davis, S. M., Pink, J. J., Yang, C. R., Araki, S., Reinicke, K. E., Bentle, M. S., Dong, Y., Cataldo, E., Criswell, T. L., Wagner, M. W., Li, L., et al. (2006). Mornings with art, lessons learned: Feedback regulation, restriction threshold biology, and redundancy govern molecular stress responses. J. Cell. Physiol. 209, 604-610.
5. Bierie, B., and Moses, H. L. (2006). Tumour microenvironment: TGFβ: The molecular Jekyll and Hyde of cancer. Nat. Rev. Cancer 6, 506-520.
6. Caporali, A., Davalli, P., Astancolle, S., D'Arca, D., Brausi, M., Bettuzzi, S., and Corti, A. (2004). The chemopreventive action of catechins in the TRAMP mouse model of prostate carcinogenesis is accompanied by clusterin over-expression. Carcinogenesis 25, 2217-2224.
7. Cervellera, M., Raschella, G., Santilli, G., Tanno, B., Ventura, A., Mancini, C., Sevignani, C., Calabretta, B., and Sala, A. (2000). Direct transactivation of the anti-apoptotic gene apolipoprotein J (clusterin) by B-MYB. J. Biol. Chem. 275, 21055-21060.
8. Chayka, O., Corvetta, D., Dews, M., Caccamo, A. E., Piotrowska, I., Santilli, G., Gibson, S., Sebire, N. J., Himoudi, N., Hogarty, M. D., Anderson, J., Bettuzzi, S., et al. (2009). Clusterin, a haploinsufficient tumour suppressor gene in neuroblastomas. J. Natl. Cancer Inst. 101, 663-677.
9. Chi, K. N., Zoubeidi, A., and Gleave, M. E. (2008). Custirsen (OGX-011): A second-generation antisense inhibitor of clusterin for the treatment of cancer. Expert Opin. Investig. Drugs 17, 1955-1962.
10. Chung, J., Kwak, C., Jin, R. J., Lee, C. H., Lee, K. H., and Lee, S. E. (2004). Enhanced chemosensitivity of bladder cancer cells to cisplatin by suppression of clusterin in vitro. Cancer Lett. 203, 155-161.
11. Cote, R., Dunn, M., Chatterjee, S., Stein, J., Shi, S., Tran, Q., Hu, S., Xu, H., Groshen, S., Taylor, C., Skinner, D., and Benedict, W. (1998). Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res. 58, 1090-1094.
12. Criswell, T., Beman, M., Araki, S., Leskov, K., Cataldo, E., Mayo, L. D., and Boothman, D. A. (2005). Delayed activation of insulin-like growth factor-1 receptor/Src/MAPK/Egr-1 signaling regulates clusterin expression, a pro-survival factor. J. Biol. Chem. 280, 14212-14221.
13. Danik, M., Chabot, J. G., Mercier, C., Benabid, A. L., Chauvin, C., Quirion, R., and Suh, M. (1991). Human gliomas and epileptic foci express high levels of a mRNA related to rat testicular sulfated glycoprotein 2, a purported marker of cell death. Proc. Natl. Acad. Sci. USA 88, 8577-8581.
14. Devauchelle, V., Essabbani, A., De Pinieux, G., Germain, S., Tourneur, L., Mistou, S., Margottin-Goguet, F., Anract, P., Migaud, H., Le Nen, D., Lequerre, T., Saraux, A., et al. (2006). Characterization and functional consequences of underexpression of clusterin in rheumatoid arthritis. J. Immunol. 177, 6471-6479.
15. Dews, M., Homayouni, A., Yu, D., Murphy, D., Sevignani, C., Wentzel, E., Furth, E. E., Lee, W. M., Enders, G. H., Mendell, J. T., and Thomas-Tikhonenko, A. (2006). Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat. Genet. 38, 1060-1065.
16. Eilers, M., Picard, D., Yamamoto, K. R., and Bishop, J. M. (1989). Chimaeras of Myc oncoprotein and steroid receptors cause hormone-dependent transformation of cells. Nature 340, 66-68.
17. Evan, G. I., and Vousden, K. H. (2001). Proliferation, cell cycle and apoptosis in cancer. Nature 411, 342-348.
18. Finnberg, N., and El-Deiry, W. S. (2008). TRAIL death receptors as tumor suppressors and drug targets. Cell Cycle 7, 1525-1528.
19. Gilmore, T. D. (2006). Introduction to NF-kappaB: Players, pathways, perspectives. Oncogene 25, 6680-6684.
20. Hellebrekers, D. M., Melotte, V., Vire, E., Langenkamp, E., Molema, G., Fuks, F., Herman, J. G., Van, C. W., Griffioen, A. W., and Van, E. M. (2007). Identification of epigenetically silenced genes in tumor endothelial cells. Cancer Res. 67, 4138-4148.
21. Herault, Y., Chatelain, G., Brun, G., and Michel, D. (1992). V-src-induced-transcription of the avian clusterin gene. Nucleic Acids Res. 20, 6377-6383.
22. Hueber, A. O., Zornig, M., Lyon, D., Suda, T., Nagata, S., and Evan, G. I. (1997). Requirement for the CD95 receptor-ligand pathway in c-Myc-induced apoptosis. Science 278, 1305-1309.
23. Ilyas, M. (2005). Wnt signalling and the mechanistic basis of tumour development. J. Pathol. 205, 130-144.
24. Ito, K., Bernardi, R., Morotti, A., Matsuoka, S., Saglio, G., Ikeda, Y., Rosenblatt, J., Avigan, D. E., Teruya-Feldstein, J., and Pandolfi, P. P. (2008). PML targeting eradicates quiescent leukaemia-initiating cells. Nature 453, 1072-1078.
25. Jiang, J., and Hui, C. C. (2008). Hedgehog signaling in development and cancer. Dev. Cell 15, 801-812.
26. Jin, G., and Howe, P. H. (1997). Regulation of clusterin gene expression by transforming growth factor β. J. Biol. Chem. 272, 26620-26626.
27. Jin, G., and Howe, P. H. (1999). Transforming growth factor β regulates clusterin gene expression via modulation of transcription factor c-Fos. Eur. J. Biochem. 263, 534-542.
28. John, B., Enright, A. J., Aravin, A., Tuschl, T., Sander, C., and Marks, D. S. (2004). Human microRNA targets. PLoS Biol. 2, e363.
29. Kadomatsu, K., Anzano, M. A., Slayter, M. V., Winokur, T. S., Smith, J. M., and Sporn, M. B. (1993). Expression of sulfated glycoprotein 2 is associated with carcinogenesis induced by N-nitroso-N-methylurea in rat prostate and seminal vesicle. Cancer Res. 53, 1480-1483.
30. Klefstrom, J., Vastrik, I., Saksela, E., Valle, J., Eilers, M., and Alitalo, K. (1994). c-Myc induces cellular susceptibility to the cytotoxic action of TNF-alpha. EMBO J. 13, 5442-5450.
31. Klock, G., Storch, S., Rickert, J., Gutacker, C., and Koch-Brandt, C. (1998). Differential regulation of the clusterin gene by Ha-ras and c-myc oncogenes and during apoptosis. J. Cell. Physiol. 177, 593-605.
32. Koch-Brandt, C., and Morgans, C. (1996). Clusterin: A role in cell survival in the face of apoptosis? Prog. Mol. Subcell. Biol. 16, 130-149.
33. Li, X., Massa, P. E., Hanidu, A., Peet, G. W., Aro, P., Savitt, A., Mische, S., Li, J., and Marcu, K. B. (2002). IKKα, IKKβ, and NEMO/IKKγ are each required for the NF-κBmediated inflammatory response program. J. Biol. Chem. 277, 45129-45140.
34. Lipsick, J. S., Manak, J., Mitiku, N., Chen, C. K., Fogarty, P., and Guthrie, E. (2001). Functional evolution of the Myb oncogene family. Blood Cells Mol. Dis. 27, 456-458.
35. Lund, P., Weisshaupt, K., Mikeska, T., Jammas, D., Chen, X., Kuban, R. J., Ungethum, U., Krapfenbauer, U., Herzel, H. P., Schafer, R., Walter, J., and Sers, C. (2006). Oncogenic HRAS suppresses clusterin expression through promoter hypermethylation. Oncogene 25, 4890-4903.
36. Lutz, W., Leon, J., and Eilers, M. (2002). Contributions of Myc to tumorigenesis. Biochim. Biophys. Acta 1602, 61-71.
37. Markopoulou, S., Kontargiris, E., Batsi, C., Tzavaras, T., Trougakos, I., Boothman, D. A., Gonos, E. S., and Kolettas, E. (2009). Vanadium-induced apoptosis of HaCaT cells is mediated by c-fos and involves nuclear accumulation of clusterin. FEBS J. 276, 3784-3799.
38. Massague, J. (2008). TGFβ in cancer. Cell 134, 215-230.
39. Mateyak, M. K., Obaya, A. J., Adachi, S., and Sedivy, J. M. (1997). Phenotypes of c-Mycdeficient rat fibroblasts isolated by targeted homologous recombination. Cell Growth Differ. 8, 1039-1048.
40. McLaughlin, L., Mistry, M., Zhu, G., Ley-Ebert, C., Stuart, W. D., Florio, C. J., Groen, P. A., Witt, S. A., Kimball, T. R., Witte, D. P., Harmony, J. A., and Aronow, B. J. (2000). Apolipoprotein J/Clusterin limits the severity of murine autoimmune myocarditis. J. Clin. Invest. 106, 1105-1113.
41. Mendell, J. T. (2008). miRiad roles for the miR-17-92 cluster in development and disease. Cell 133, 217-222.
42. Meyer, N., and Penn, L. Z. (2008). Reflecting on 25 years with MYC. Nat. Rev. Cancer 8, 976-990.
43. Michel, D., Gillet, G., Volovitch, M., Pessac, B., Calothy, G., and Brun, G. (1989). Expression of a novel gene encoding a 51.5 kD precursor protein is induced by different retroviral oncogenes in quail neuroretinal cells. Oncogene Res. 4, 127-136.
44. Miyake, H., Hara, I., Kamidono, S., Gleave, M. E., and Eto, H. (2003). Resistance to cytotoxic chemotherapy-induced apoptosis in human prostate cancer cells is associated with intracellular clusterin expression. Oncol. Rep. 10, 469-473.
45. Miyake, H., Hara, I., and Gleave, M. E. (2005). Antisense oligodeoxynucleotide therapy targeting clusterin gene for prostate cancer: Vancouver experience from discovery to clinic. Int. J. Urol. 12, 785-794.
46. Morgenbesser, S. D., and DePinho, R. A. (1994). Use of transgenic mice to study myc family gene function in normal mammalian development and in cancer. Semin. Cancer Biol. 5, 21-36.
47. Morris, E. J., Ji, J. Y., Yang, F., Di Stefano, L., Herr, A., Moon, N. S., Kwon, E. J., Haigis, K. M., Naar, A. M., and Dyson, N. J. (2008). E2F1 represses beta-catenin transcription and is antagonized by both pRB and CDK8. Nature 455, 552-556.
48. Nakajima, T., Yasui, K., Zen, K., Inagaki, Y., Fujii, H., Minami, M., Tanaka, S., Taniwaki, M., Itoh, Y., Arii, S., Inazawa, J., and Okanoue, T. (2008). Activation of B-Myb by E2F1 in hepatocellular carcinoma. Hepatol. Res. 38, 886-895.
49. Narita, S., So, A., Ettinger, S., Hayashi, N., Muramaki, M., Fazli, L., Kim, Y., and Gleave, M. E. (2008). GLI2 knockdown using an antisense oligonucleotide induces apoptosis and chemosensitizes cells to paclitaxel in androgen-independent prostate cancer. Clin. Cancer Res. 14, 5769-5777.
50. Nusse, R. (1992). The Wnt gene family in tumorigenesis and in normal development. J. Steroid Biochem. Mol. Biol. 43, 9-12.
51. Nuutinen, T., Suuronen, T., Kyrylenko, S., Huuskonen, J., and Salminen, A. (2005). Induction of clusterin/apoJ expression by histone deacetylase inhibitors in neural cells. Neurochem. Int. 47, 528-538.
52. O'Donnell, K. A., Wentzel, E. A., Zeller, K. I., Dang, C. V., and Mendell, J. T. (2005). c-Mycregulated microRNAs modulate E2F1 expression. Nature 435, 839-843.
53. Oh, I. H., and Reddy, E. P. (1999). The myb gene family in cell growth, differentiation and apoptosis. Oncogene 18, 3017-3033.
54. Orlandi, A., Pucci, S., Ciucci, A., Pichiorri, F., Ferlosio, A., and Spagnoli, L. G. (2005). Modulation of clusterin isoforms is associated with all-trans retinoic acid-induced proliferative arrest and apoptosis of intimal smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 25, 348-353.
55. Patterson, S. G., Wei, S., Chen, X., Sallman, D. A., Gilvary, D. L., Zhong, B., Pow-Sang, J., Yeatman, T., and Djeu, J. Y. (2006). Novel role of Stat1 in the development of docetaxel resistance in prostate tumor cells. Oncogene 25, 6113-6122.
56. Perkins, N. D. (2007). Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat. Rev. Mol. Cell. Biol. 8, 49-62.
57. Pierce, A. M., Schneider-Broussard, R., Gimenez-Conti, I. B., Russell, J. L., Conti, C. J., and Johnson, D. G. (1999). E2F1 has both oncogenic and tumor-suppressive properties in a transgenic model. Mol. Cell. Biol. 19, 6408-6414.
58. Polakis, P. (2000). Wnt signaling and cancer. Genes Dev. 14, 1837-1851.
59. Raschella, G., Cesi, V., Amendola, R., Negroni, A., Tanno, B., Altavista, P., Tonini, G. P., De Bernardi, B., and Calabretta, B. (1999). Expression of B-myb in neuroblastoma tumors is a poor prognostic factor independent from MYCN amplification. Cancer Res. 59, 3365-3368.
60. Rask, K., Nilsson, A., Brannstrom, M., Carlsson, P., Hellberg, P., Janson, P. O., Hedin, L., and Sundfeldt, K. (2003). Wnt-signalling pathway in ovarian epithelial tumours: Increased expression of beta-catenin and GSK3beta. Br. J. Cancer 89, 1298-1304.
61. Rauhala, H. E., Porkka, K. P., Saramaki, O. R., Tammela, T. L., and Visakorpi, T. (2008). Clusterin is epigenetically regulated in prostate cancer. Int. J. Cancer 123, 1601-1609.
62. Ricci, S., Jin, Z., Dews, M., Yu, D., Thomas-Tikhonenko, A., Dicker, D. T., and El-Deiry, W. S. (2004). Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity. Mol. Cell. Biol. 24, 8541-8555.
63. Sala, A., and Watson, R. (1999). B-Myb protein in cellular proliferation, transcription control, and cancer: Latest developments. J. Cell. Physiol. 179, 245-250.
64. Sallman, D. A., Chen, X., Zhong, B., Gilvary, D. L., Zhou, J., Wei, S., and Djeu, J. Y. (2007). Clusterin mediates TRAIL resistance in prostate tumor cells. Mol. Cancer Ther. 6, 2938-2947.
65. Santilli, G., Aronow, B. J., and Sala, A. (2003). Essential requirement of apolipoprotein J (clusterin) signaling for IkappaB expression and regulation of NF-kappaB activity. J. Biol. Chem. 278, 38214-38219.
66. Santilli, G., Schwab, R., Watson, R., Ebert, C., Aronow, B. J., and Sala, A. (2005). Temperaturedependent modification and activation of B-MYB: Implications for cell survival. J. Biol. Chem. 280, 15628-15634.
67. Saura, J., Petegnief, V., Wu, X., Liang, Y., and Paul, S. M. (2003). Microglial apolipoprotein E and astroglial apolipoprotein J expression in vitro: Opposite effects of lipopolysaccharide. J. Neurochem. 85, 1455-1467.
68. Savkovic, V., Gantzer, H., Reiser, U., Selig, L., Gaiser, S., Sack, U., Kloppel, G., Mossner, J., Keim, V., Horn, F., and Bodeker, H. (2007). Clusterin is protective in pancreatitis through antiapoptotic and anti-inflammatory properties. Biochem. Biophys. Res. Commun. 356, 431-437.
69. Scaltriti, M., Bettuzzi, S., Sharrard, R. M., Caporali, A., Caccamo, A. E., and Maitland, N. J. (2004a). Clusterin overexpression in both malignant and nonmalignant prostate epithelial cells induces cell cycle arrest and apoptosis. Br. J. Cancer 91, 1842-1850.
70. Scaltriti, M., Brausi, M., Amorosi, A., Caporali, A., D'Arca, D., Astancolle, S., Corti, A., and Bettuzzi, S. (2004b). Clusterin (SGP-2, ApoJ) expression is downregulated in low- and highgrade human prostate cancer. Int. J. Cancer 108, 23-30.
71. Scaltriti, M., Santamaria, A., Paciucci, R., and Bettuzzi, S. (2004c). Intracellular clusterin induces G(2)-M phase arrest and cell death in PC-3 prostate cancer cells. Cancer Res. 64, 6174-6182.
72. Schepeler, T., Mansilla, F., Christensen, L. L., Orntoft, T. F., and Andersen, C. L. (2007). Clusterin expression can be modulated by changes in TCF1-mediated Wnt signaling. J. Mol. Signal. 2, 6.
73. Takase, O., Marumo, T., Hishikawa, K., Fujita, T., Quigg, R. J., and Hayashi, M. (2008a). NFkappaB-dependent genes induced by proteinuria and identified using DNA microarrays. Clin. Exp. Nephrol. 12, 181-188.
74. Takase, O., Minto, A. W., Puri, T. S., Cunningham, P. N., Jacob, A., Hayashi, M., and Quigg, R. J. (2008b). Inhibition of NF-kappaB-dependent Bcl-xL expression by clusterin promotes albumin-induced tubular cell apoptosis. Kidney Int. 73, 567-577.
75. Tarasov, K. V., Tarasova, Y. S., Tam, W. L., Riordon, D. R., Elliott, S. T., Kania, G., Li, J., Yamanaka, S., Crider, D. G., Testa, G., Li, R. A., Lim, B., et al. (2008). B-MYB is essential for normal cell cycle progression and chromosomal stability of embryonic stem cells. PloS ONE 3, e2478.
76. Thomas-Tikhonenko, A., Viard-Leveugle, I., Dews, M., Wehrli, P., Sevignani, C., Yu, D., Ricci, S., El-Deiry, W. S., Aronow, B., Kaya, G., Saurat, J.-H., and French, L. E. (2004). Myc-transformed epithelial cells down-regulate clusterin which inhibits their growth in vitro and carcinogenesis in vivo. Cancer Res. 64, 3126-3136.
77. Trumpp, A., Refaeli, Y., Oskarsson, T., Gasser, S., Murphy, M., Martin, G. R., and Bishop, J. M. (2001). c-Myc regulates mammalian body size by controlling cell number but not cell size. Nature 414, 768-773.
78. Viale, A., De Franco, F., Orleth, A., Cambiaghi, V., Giuliani, V., Bossi, D., Ronchini, C., Ronzoni, S., Muradore, I., Monestiroli, S., Gobbi, A., Alcalay, M., et al. (2009). Cell-cycle restriction limits DNA damage and maintains self-renewal of leukaemia stem cells. Nature 457, 51-56.
79. Villavicencio, E. H., Walterhouse, D. O., and Iannaccone, P. M. (2000). The sonic hedgehogpatched-gli pathway in human development and disease. Am. J. Hum. Genet. 67, 1047-1054.
80. Vita, M., and Henriksson, M. (2006). The Myc oncoprotein as a therapeutic target for human cancer. Semin. Cancer Biol. 16, 318-330.
81. Volinia, S., Calin, G. A., Liu, C. G., Ambs, S., Cimmino, A., Petrocca, F., Visone, R., Iorio, M., Roldo, C., Ferracin, M., Prueitt, R. L., Yanaihara, N., et al. (2006). A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl. Acad. Sci. USA 103, 2257-2261.
82. Yang, C. R., Leskov, K., Hosley-Eberlein, K., Criswell, T., Pink, J. J., Kinsella, T. J., and Boothman, D. A. (2000). Nuclear clusterin/XIP8, an X-ray-induced Ku70-binding protein that signals cell death. Proc. Natl. Acad. Sci. USA 97, 5907-5912.
83. Yaylim-Eraltan, I., Bozkurt, N., Ergen, A., Zeybek, U., Ozturk, O., Arikan, S., Erbil, Y., Uslu, I., Camlica, H., and Isbir, T. (2008). L-myc gene polymorphism and risk of thyroid cancer. Exp. Oncol. 30, 117-120.
84. Zindy, F., Eischen, C. M., Randle, D. H., Kamijo, T., Cleveland, J. L., Sherr, C. J., and Roussel, M. F. (1998). Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev. 12, 2424-2433.